BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Bristol-Myers Squibb Pharma EEIG submitted on 30 September 2004 an application for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Baraclude  (entecavir), 
through  the  centralised  procedure.  The  eligibility  to  the  centralised  procedure  by  the  CHMP  was 
agreed upon on 29 July 2004. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. B. Ljungberg 
Co-Rapporteur:  Dr. E. Abadie 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
A new application was filed in the following countries: USA (30/09/2004). 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 30 September 2004.  
The procedure started on 18 October 2004. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
30 December 2004. The Co-Rapporteur's first Assessment Report was circulated to all CHMP 
members on 28 December 2004. 
During the meeting on 14 – 17 February 2005, the CHMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 17 February 2005. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  18 
November 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 2 January 2006. 
During the CHMP meeting on 23-26 January 2006, the CHMP agreed on a list of outstanding 
issues  to  be  addressed  in  writing  by  the  applicant.  The  final  consolidated  List  of  Outstanding 
issues was sent to the applicant on 26 January 2006. 
The applicant submitted the responses to the CHMP list of outstanding issues on 13 February 
2006.  
The Rapporteurs circulated a Joint Assessment Report on the applicant’s responses to the List of 
outstanding issues to all CHMP members on 3 March 2006. 
Based on preliminary responses provided by the applicant on 10 March 2006, the Rapporteurs 
circulated an updated Joint Assessment Report to all CHMP members on 17 March 2006. 
During  the  CHMP  meeting  on  20-23  March  2006,  the  CHMP  agreed  on  a  second  list  of 
outstanding  issues  to  be  addressed  in  writing  by  the  applicant.  The  final  consolidated  List  of 
Outstanding issues was sent to the applicant on 23 March 2006. 
The  applicant  submitted  the  responses  to  the  second  CHMP  list  of  outstanding  issues  on  31 
March 2006. 
The Rapporteurs circulated a Joint Assessment Report on the applicant’s responses to the List of 
outstanding issues to all CHMP members on 10 April 2006. 
During the meeting on 24-27 April 2006, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
1/2 
©EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
 
• 
Marketing  Authorisation  to  Baraclude  on  27  April  2006.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 24 April 2006. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 26 June 2006. 
2/2 
©EMEA 2006 
 
 
 
